Trial Profile
An Open Label, Dose Ranging, Exploratory Study to Evaluate the Safety, Tolerability, Compliance, Mechanism of Action and Efficacy of QBECO Site Specific Immunomodulation for the Induction of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2017
Price :
$35
*
At a glance
- Drugs QBECO (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Qu Biologics
- 19 Dec 2017 According to a Qu Biologics media release, data from this clinical trial will be presented at the inaugural Crohn's and Colitis Congress in Jan 2018.
- 02 Aug 2017 Results published in the Qu Biologics media release
- 27 Dec 2016 Status changed from active, no longer recruiting to completed.